This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spirito, P. Articles by Maron, B. J. Search for Related Content PubMed PubMed Citation Articles by Spirito, P. Articles by Maron, B. J.

Circulation, Vol 67, 1100-1108, Copyright © 1983 by American Heart Association

ARTICLES

Significance of left ventricular outflow tract cross-sectional area in hypertrophic cardiomyopathy: a two-dimensional echocardiographic assessment

P Spirito and BJ Maron

The morphologic determinants of subaortic obstruction in patients with hypertrophic cardiomyopathy are not completely understood. To define the relation between left ventricular outflow tract orifice size and presence or absence of subaortic obstruction, we studied 65 patients with hypertrophic cardiomyopathy and 16 normal controls by quantitative two-dimensional echocardiography. Left ventricular outflow tract area was measured at the onset of systole in the short-axis view in the stop- frame mode. Left ventricular outflow tract area was significantly smaller in patients with hypertrophic cardiomyopathy and subaortic obstruction (2.6 +/- 0.7 cm2) than in patients without obstruction (5.9 +/- 1.6 cm2, p less than 0.001). Twenty of 21 patients with obstruction had a left ventricular outflow tract area smaller than 4.0 cm2, whereas 28 of 30 patients without obstruction had a left ventricular outflow tract area of 4.0 cm2 or greater. The outflow tract area in patients with provocable obstruction (4.6 +/- 1.6 cm2) was intermediate between the areas of patients with and without obstruction. Left ventricular outflow tract area was significantly smaller in patients with hypertrophic cardiomyopathy (4.6 +/- 2.0 cm2) than in normal subjects (10.4 +/- 1.2 cm2, p less than 0.001). We conclude that the cross- sectional outflow tract area is closely related to the presence or absence of subaortic obstruction in patients with hypertrophic cardiomyopathy. Hence, the size of the outflow tract at the level of the mitral valve appears to be of major pathophysiologic significance in producing obstruction in these patients.

This article has been cited by other articles:

				C. van der Lee, F. J. ten Cate, M. L. Geleijnse, M. J. Kofflard, C. Pedone, L. A. van Herwerden, E. Biagini, W. B. Vletter, and P. W. Serruys Percutaneous Versus Surgical Treatment for Patients With Hypertrophic Obstructive Cardiomyopathy and Enlarged Anterior Mitral Valve Leaflets Circulation, July 26, 2005; 112(4): 482 - 488. [Abstract] [Full Text] [PDF]

				J. X. Qin, T. Shiota, H. M. Lever, D. N. Rubin, F. Bauer, Y. J. Kim, M. Sitges, N. L. Greenberg, J. K. Drinko, M. Martin, et al. Impact of left ventricular outflow tract area on systolic outflow velocity in hypertrophic cardiomyopathy: A real-time three-dimensional echocardiographic study J. Am. Coll. Cardiol., January 16, 2002; 39(2): 308 - 314. [Abstract] [Full Text] [PDF]

				F.A. Schoendube Surgical treatment of hypertrophic obstructive cardiomyopathy Eur. Heart J. Suppl., October 1, 2001; 3(suppl_L): L26 - L31. [Abstract] [PDF]

				M. V. Sherrid, D. Z. Gunsburg, S. Moldenhauer, and G. Pearle Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1344 - 1354. [Abstract] [Full Text] [PDF]

				A. P. R. M. Osterop, M. J. M. Kofflard, L. A. Sandkuijl, F. J. t. Cate, R. Krams, M. A. D. H. Schalekamp, and A. H. J. Danser AT1 Receptor A/C1166 Polymorphism Contributes to Cardiac Hypertrophy in Subjects With Hypertrophic Cardiomyopathy Hypertension, November 1, 1998; 32(5): 825 - 830. [Abstract] [Full Text] [PDF]

				J. A.M. van Son, R. H. Anderson, and F. W. Mohr Cephalad resuspension of aortic leaflet of the mitral valve in hypertrophic obstructive cardiomyopathy Ann. Thorac. Surg., July 1, 1998; 66(1): 242 - 244. [Abstract] [Full Text] [PDF]

				M. Hamada, Y. Shigematsu, S. Ikeda, Y. Hara, H. Okayama, K. Kodama, T. Ochi, and K. Hiwada Class Ia Antiarrhythmic Drug Cibenzoline : A New Approach to the Medical Treatment of Hypertrophic Obstructive Cardiomyopathy Circulation, September 2, 1997; 96(5): 1520 - 1524. [Abstract] [Full Text]

				P. Spirito, C. E. Seidman, W. J. McKenna, and B. J. Maron The Management of Hypertrophic Cardiomyopathy N. Engl. J. Med., March 13, 1997; 336(11): 775 - 785. [Full Text] [PDF]

				P. R. Fox, S.-K. Liu, and B. J. Maron Echocardiographic Assessment of Spontaneously Occurring Feline Hypertrophic Cardiomyopathy : An Animal Model of Human Disease Circulation, November 1, 1995; 92(9): 2645 - 2651. [Abstract] [Full Text]

				R. A. Levine, G. J. Vlahakes, X. Lefebvre, J. L. Guerrero, E. G. Cape, A. P. Yoganathan, and A. E. Weyman Papillary Muscle Displacement Causes Systolic Anterior Motion of the Mitral Valve : Experimental Validation and Insights Into the Mechanism of Subaortic Obstruction Circulation, February 15, 1995; 91(4): 1189 - 1195. [Abstract] [Full Text]